- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ciprofloxacin exposure not tied to miscarriage, major malformations: Study
Denmark: A recent study in the journal BJOG: An International Journal of Obstetrics & Gynaecology showed no link between maternal exposure to ciprofloxacin within the first 22 weeks of pregnancy and the risk of miscarriage and major malformations.
Ciprofloxacin is the antibiotic of choice for initial prophylactic therapy among asymptomatic pregnant women exposed to Bacillus anthracis, according to the US Food and Drug Administration (FDA). While, the FDA further states that, there have been no controlled studies of ciprofloxacin use in pregnant women to show safety. However, an expert review of published data on experiences with ciprofloxacin use during pregnancy by TERIS showed that t therapeutic doses during pregnancy are not likely to pose a substantial teratogenic risk, but there is insufficient data to state that there is no risk.
Against the above background, Mia Noergaard, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark, and colleagues aimed to examine the association between maternal exposure to ciprofloxacin and the risk of miscarriage and major malformations in a nationwide register-based cohort study.
For this purpose, the researchers obtained data from the Medical Birth Registry, the National Hospital Registry, the Danish National Prescription Registry, and Statistics Denmark between 1997-2016. It included all registered pregnancies that ended in an elective termination, miscarriage, stillbirth, or live birth. Exposure was defined as redeeming one or more prescriptions of ciprofloxacin.
Miscarriage was defined as a diagnosis given before 22 weeks without any medical intervention. According to EUROCAT 1.4, major malformations were classified. Ciprofloxacin-exposed pregnancies were matched o unexposed pregnancies on the propensity score in a ratio of 1:4. The hazard ratio (HR) of miscarriage was estimated. Also, the relative risk ratio (RR) of major malformations was estimated.
The study revealed the following findings:
- A total of 1,650,649 pregnancies were identified. Of these, 10,250 (2,050 ciprofloxacin exposed) and 6,100 (1,220 ciprofloxacin exposed) were included in the miscarriage and major malformation analysis, respectively.
- The HR of miscarriage was 0.99.
- For major malformation, the RR was 1.01.
- For the organ-specific major malformations and the sensitivity analyses, no significant increased risks were identified.
To conclude, there was no association between miscarriage and maternal ciprofloxacin exposure within the first 22 weeks of pregnancy, or major malformations and maternal exposure during the first trimester.
Reference:
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751